Proud to present PDX Pharma’s new research article in collaboration with OHSU. “PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.” published in Cancer Letters.
Lung cancer is by far the leading cause of cancer death in men and women. Herein we utilize our nanoparticle platform for co-delivery of well rationale molecular targeted compounds to treat lung cancer.
We report novel cetuximab conjugated nanoparticle delivering PLK1 siRNA (C-siPLK1-NP).
C-siPLK1-NP can treat NSCLC as a single agent and sensitize the cancer to radiation.
Systemic treatment reduces orthotopic lung tumor growth in mice and prolongs survival.
C-siPLK1-NP also has potential application in EGFR + breast and colorectal cancer.